Abnova (Taiwan) Corporation (TPE:4133)
21.05
+0.50 (2.43%)
May 29, 2026, 1:30 PM CST
Abnova (Taiwan) Revenue
Abnova (Taiwan) had revenue of 87.91M TWD in the quarter ending March 31, 2026, a decrease of -2.86%. This brings the company's revenue in the last twelve months to 348.71M, down -3.34% year-over-year. In the year 2025, Abnova (Taiwan) had annual revenue of 351.30M, down -1.11%.
Revenue (ttm)
348.71M
Revenue Growth
-3.34%
P/S Ratio
3.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 351.30M | -3.96M | -1.11% |
| Dec 31, 2024 | 355.26M | -26.80M | -7.01% |
| Dec 31, 2023 | 382.05M | -29.70M | -7.21% |
| Dec 31, 2022 | 411.76M | -39.73M | -8.80% |
| Dec 31, 2021 | 451.49M | -4.96M | -1.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 718.58M |
| Meribank Biotech | 471.76M |
| GenMont Biotech Incorporation | 401.23M |
| NeoCore Technology | 235.54M |
| GeneReach Biotechnology | 232.55M |
| Enimmune | 48.19M |
| Holy Stone Healthcare | 47.51M |